Medication info
Bonkey Soft Capsule (Calcitriol)

Bonkey Soft Capsule (Calcitriol)

Prescription medicationSoft capsuleOral
Ingredient · strength
Calcitriol›0.25μg / 1 capsule
Manufacturer / importer
Yuyu Pharmaceutical Co., Ltd.
Appearance
Ovoid soft capsules containing a colorless or transparent liquid, appearing milky.
Packaging
30 capsules (10 capsules/PTPX3), 60 capsules (10 capsules/PTPX6), 100 capsules/bottle
Approval status
Active

MFDS item code 199300288 · Notified 1993.01.14 · Insurance code 644500390

Summary

Main use
Treatment of bone diseases (osteoporosis, rickets, etc.), renal bone disease, and parathyroid dysfunction
Who takes it
Adults · Children
Adult dose
The optimal daily dose of this drug should be carefully determined for each patient based on serum calcium levels. Initiate treatment at the lowest possible dose, and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The recommended initial adult dose is 0.25 ㎍ of calcitriol once daily; if necessary, the dose may be increased to 0.5 ㎍ once daily. ○ Renal osteodystrophy (patients on dialysis): The initial daily dose is 0.25 ㎍ of this drug. For patients with serum calcium levels in the normal range or slightly below normal, administer 0.25 ㎍ every other day. If there is an inadequate response in laboratory values and clinical symptoms, increase the dose by 0.25 ㎍ per day at intervals of 2 ~ 4 weeks. During this period, serum calcium levels should be measured at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ daily. This drug improves calcium absorption from the gastrointestinal tract, so some patients taking this drug may be maintained on a lower calcium intake. Patients prone to hypercalcemia may require only a small amount of calcium or no calcium supplementation at all. ○ Osteoporosis: Administer 0.25 ㎍ of this drug twice daily. During the dose stabilization period, serum calcium levels should be measured at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium levels return to normal. Since treatment with this drug increases calcium absorption in patients with postmenopausal osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: It is advisable to administer an initial dose of 0.25 ㎍ of this drug every morning. If there is an inadequate response in laboratory values and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, serum calcium levels should be measured at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so a higher dose may be required. ○ General: Once the optimal dose of this drug has been determined, serum calcium levels should be measured once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, immediately reduce the dose sufficiently or discontinue treatment until serum calcium levels return to normal. Discontinuing additional calcium supplementation is also effective for rapidly normalizing serum calcium levels. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, serum calcium and phosphorus levels should be measured daily. Once levels return to normal, continue treatment at a dose 0.25 ㎍ per day lower than the previous dose.
Child dose
Children aged 36 months and older: 0.25 ㎍ of calcitriol daily; if necessary, the dose may be increased to 0.5 ㎍ daily. Children under 36 months: The recommended initial dose is 10 ~ 15 ng per kg of body weight daily.

Ingredients

Manufacturer
Yuyu Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of bone diseases (osteoporosis, rickets, etc.), renal bone disease, and parathyroid dysfunction

  • Chronic renal failure
  • secondary hyperparathyroidism
  • metabolic bone disease
  • hypoparathyroidism
  • rickets
  • osteomalacia
  • osteoporosis
  • renal osteodystrophy
View approved original text

This medication is used to treat secondary hyperparathyroidism and associated metabolic bone diseases in patients with chronic renal failure before dialysis treatment. It is also helpful in treating renal osteodystrophy in patients undergoing hemodialysis. It is effective for hypoparathyroidism, including post-surgical, idiopathic, and pseudohypoparathyroidism. It is used for conditions like vitamin D-dependent rickets or hypophosphatemic vitamin D-resistant rickets, as well as osteomalacia. Finally, it helps in the treatment of osteoporosis, addressing various bone-related issues.

How to take

Adult dose

The optimal daily dose of this drug should be carefully determined for each patient based on serum calcium levels. Initiate treatment at the lowest possible dose, and do not increase the dose without close monitoring of serum calcium. ○ Patients before the dialysis stage: The recommended initial adult dose is 0.25 ㎍ of calcitriol once daily; if necessary, the dose may be increased to 0.5 ㎍ once daily. ○ Renal osteodystrophy (patients on dialysis): The initial daily dose is 0.25 ㎍ of this drug. For patients with serum calcium levels in the normal range or slightly below normal, administer 0.25 ㎍ every other day. If there is an inadequate response in laboratory values and clinical symptoms, increase the dose by 0.25 ㎍ per day at intervals of 2 ~ 4 weeks. During this period, serum calcium levels should be measured at least twice weekly. Most patients respond to doses of 0.5 ~ 1.0 ㎍ daily. This drug improves calcium absorption from the gastrointestinal tract, so some patients taking this drug may be maintained on a lower calcium intake. Patients prone to hypercalcemia may require only a small amount of calcium or no calcium supplementation at all. ○ Osteoporosis: Administer 0.25 ㎍ of this drug twice daily. During the dose stabilization period, serum calcium levels should be measured at least twice weekly. If hypercalcemia is observed, discontinue treatment until serum calcium levels return to normal. Since treatment with this drug increases calcium absorption in patients with postmenopausal osteoporosis, calcium supplementation may not be necessary. ○ Hypoparathyroidism and rickets/osteomalacia: It is advisable to administer an initial dose of 0.25 ㎍ of this drug every morning. If there is an inadequate response in laboratory values and clinical symptoms, increase the dose at intervals of 2 ~ 4 weeks. During dose determination, serum calcium levels should be measured at least twice weekly. Malabsorption sometimes occurs in patients with hypoparathyroidism, so a higher dose may be required. ○ General: Once the optimal dose of this drug has been determined, serum calcium levels should be measured once monthly. Blood samples for serum calcium measurement should be collected without a tourniquet. If serum calcium rises by 1 mg/dL (250 μmol/L) above the normal range of 9 ~ 11 mg/dL (2,250 ~ 2,750 μmol/L), or serum creatinine rises to 120 μmol/L or higher, immediately reduce the dose sufficiently or discontinue treatment until serum calcium levels return to normal. Discontinuing additional calcium supplementation is also effective for rapidly normalizing serum calcium levels. Carefully consider reducing dietary calcium intake as well. During hypercalcemia, serum calcium and phosphorus levels should be measured daily. Once levels return to normal, continue treatment at a dose 0.25 ㎍ per day lower than the previous dose.

Child dose

Children aged 36 months and older: 0.25 ㎍ of calcitriol daily; if necessary, the dose may be increased to 0.5 ㎍ daily. Children under 36 months: The recommended initial dose is 10 ~ 15 ng per kg of body weight daily.

Precautions

This medication should not be used by patients with conditions related to hypercalcemia or hypercalciuria. Patients with allergic reactions to this drug or its ingredients should also refrain from using it. Women who are pregnant or breastfeeding should use this medication cautiously, and special attention is needed for young children or patients with a history of kidney stones. This drug is an active form of vitamin D, and overdose may result in hypercalcemia, which can manifest with symptoms like nausea, vomiting, constipation, headache, insomnia, palpitations, and more. During treatment, serum calcium and phosphorus levels should be regularly monitored to maintain them within the normal range. Calcium intake should be limited to an appropriate amount, as excessive intake increases the risk of side effects. Caution should be exercised when taken with other vitamin D products or calcium supplements, as this may increase the risk of hypercalcemia. Interaction may occur particularly with diuretics or digoxin, so it is necessary to consult healthcare providers. In cases of overdose, emergency measures such as inducing vomiting or gastric lavage may be needed, and the condition should be closely monitored through blood tests and electrocardiograms. This medication requires careful dosage adjustments and attention for children, the elderly, and patients with impaired kidney function. Pregnant or nursing women should take it based on a doctor's discretion, and calcium levels in both the mother and baby should be monitored while breastfeeding. Driving or operating machinery is safe within the recommended dosage, but caution is needed in case of overdose. This medication should be stored away from direct sunlight and moisture, below 25 degrees Celsius, and kept out of reach of children.

Side effects

  • nausea
  • diarrhea
  • loss of appetite
  • constipation
  • vomiting
  • gastric discomfort
  • abdominal pain
  • thirst
  • abdominal cramping
  • ileus
Show 88 more
  • gastric pain
  • abdominal discomfort
  • epigastric pain
  • abdominal distension
  • stomatitis
  • polydipsia and thirst
  • pancreatitis
  • metallic taste
  • restlessness
  • anxiety
  • insomnia
  • headache
  • apathy
  • drowsiness
  • psychosis
  • depression
  • coma
  • palpitations
  • deep vein thrombosis
  • hypertension
  • sensory disturbances
  • calcification around joints
  • bone pain
  • rhinorrhea
  • epistaxis
  • urinary tract infection
  • urolithiasis
  • elevated AST
  • elevated ALT
  • elevated LDH
  • elevated BUN
  • elevated creatinine
  • elevated serum uric acid
  • nephrocalcinosis
  • nephrolithiasis
  • itching
  • urticaria
  • rash
  • dry skin
  • conjunctivitis
  • conjunctival hyperemia
  • photophobia
  • weakness
  • limb pain
  • polyuria
  • nocturia
  • dehydration
  • elevated ALP
  • hypermagnesemia
  • hypercalciuria
  • hyperphosphatemia
  • lymphocytosis
  • increased hematocrit
  • neutrophilia
  • increased hemoglobin
  • fatigue
  • abdominal cramps
  • fever with thirst
  • chest pain
  • menstrual disorders
  • flushing
  • low back pain
  • limb pain
  • coldness in limbs
  • edema
  • metastatic calcification
  • myasthenia
  • nutritional disorders
  • weight loss
  • high fever
  • myalgia
  • proteinuria
  • growth retardation
  • hypercalcemia
  • hypercholesterolemia
  • decreased libido
  • loss of appetite
  • headache
  • vomiting
  • constipation
  • atrophic changes
  • sensory disturbances
  • fever with thirst
  • polyuria
  • dehydration
  • lethargy
  • growth inhibition
  • urinary tract infection

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it must be kept in a tightly sealed container. It should be stored at a normal room temperature, away from extreme heat or cold.

Appearance and packaging

Appearance

Ovoid soft capsules containing a colorless or transparent liquid, appearing milky.

Package unit

30 capsules (10 capsules/PTPX3), 60 capsules (10 capsules/PTPX6), 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.